INTERINDIVIDUAL DIFFERENCES IN NICOTINE METABOLISM AND GENETIC POLYMORPHISMS OF HUMAN CYP2A6

REFERENCES

• Russell M.A.H., Feyerabend C. Cigarette Smoking: A Dependence on High-Nicotine Boli. Drug Metab. Rev. 1978; 8: 29–57
   PubMed Web of Science ®Google Scholar
• Benowitz N.L., Jacob P., III. Metabolism, Pharmacokinetics, and Pharmacodynamics of Nicotine in Man. Tobacco Smoking and Nicotine: A Neurobiological Approach, W.R. Marton, G.R. VanLoon, E.T. Iwamoto, L. Davis. Plenum Press, New York 1987; 357–373
   Google Scholar
• Benowitz N.L., Jacob P., III, Fong I., Gupta S. Nicotine Metabolic Profile in Man: Comparison of Cigarette Smoking and Transdermal Nicotine. J. Pharmacol. Exp. Ther. 1994; 268: 296–303
   PubMed Web of Science ®Google Scholar
• Nakajima M., Yamamoto T., Nunoya K.-I., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Role of Human Cytochrome P4502A6 in C-Oxidation of Nicotine. Drug Metab. Dispos. 1996; 24: 1212–1217
   PubMed Web of Science ®Google Scholar
• Nakajima M., Yamamoto T., Nunoya K.-I., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Characterization of CYP2A6 Involved in 3′-Hydroxylation of Cotinine in Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1996; 277: 1010–1015
   PubMed Web of Science ®Google Scholar
• Cholerton S., Arpanahi A., McCracken N., Boustead C., Taber H., Johnstone E., Leathart J., Daly A.K., Idle J.R. Poor Metabolisers of Nicotine and CYP2D6 Polymorphism. Lancet 1994; 343: 62–63
   PubMed Web of Science ®Google Scholar
• Benowitz N.L., Jacob P., III, Sachs D.P.L. Deficient C-Oxidation of Nicotine. Clin. Pharmacol. Ther. 1995; 57: 590–594
   PubMed Web of Science ®Google Scholar
• Nakajima M., Yamamoto T., Kuroiwa Y., Yokoi T. Improved Highly Sensitive Method for Determination of Nicotine and Cotinine in Human Plasma by High-Performance Liquid Chromatography. J. Chromatogr. B 2000; 742: 211–215
   PubMed Web of Science ®Google Scholar
• Nakajima M., Yamagishi S.-I., Yamamoto H., Yamamoto T., Kuroiwa Y., Yokoi T. Deficient Cotinine Formation from Nicotine Is Attributed to the Whole Deletion of the CYP2A6 Gene in Humans. Clin. Pharmacol. Ther. 2000; 67: 57–69
   PubMed Web of Science ®Google Scholar
• Nakajima M., Kwon J.-T., Tanaka N., Zenta T., Yamamoto Y., Yamamoto H., Yamazaki H., Yamamoto T., Kuroiwa Y., Yokoi T. Relationship Between Interindividual Differences in Nicotine Metabolism and CYP2A6 Genetic Polymorphism in Humans. Clin. Pharmacol. Ther. 2001; 69: 72–78
   PubMed Web of Science ®Google Scholar
• Kwon J.-T., Nakajima M., Chai S., Yom Y.-K., Kim H.-K., Yamazaki H., Sohn D.-R., Yamamoto T., Kuroiwa Y., Yokoi T. Nicotine Metabolism and CYP2A6 Allele Frequencies in Koreans. Pharmacogenetics 2001; 11: 317–323
   PubMedGoogle Scholar
• Fernandez-Salguero P., Gonzalez F.J. The CYP2A Gene Subfamily: Species Differences, Regulation, Catalytic Activities and Role in Chemical Carcinogenesis. Pharmacogenetics 1995; 5: S123–S128
   PubMedGoogle Scholar
• Yamano S., Tatsuno J., Gonzalez F.J. The CYP2A3 Gene Product Catalyzes Coumarin 7-Hydroxylation in Human Liver Microsomes. Biochemistry 1990; 29: 1322–1329
   PubMed Web of Science ®Google Scholar
• Ding S., Lake B.G., Friedberg T., Wolf C.R. Expression and Alternative Splicing of the Cytochrome P450 CYP2A7. Biochem. J. 1995; 306: 161–166
   PubMed Web of Science ®Google Scholar
• Oscarson M., McLellan R.A., Gullstén H., Agúndez J.A.G., Benítez J., Rautio A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Identification and Characterization of Novel Polymorphisms in the CYP2A Locus: Implications for Nicotine Metabolism. FEBS Lett. 1999; 460: 321–327
   PubMed Web of Science ®Google Scholar
• Fernandez-Salguero P., Hoffman S.M.G., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., Pelkonen O., Huang J.-D., Evans W.E., Idle J.R. A Genetic Polymorphism in Coumarin 7-Hydroxylation: Sequence of the Human CYP2A Genes and Identification of Variant CYP2A6 Alleles. Am. J. Hum. Genet. 1995; 57: 651–660
   PubMed Web of Science ®Google Scholar
• Nunoya K.-I., Yokoi T., Takahashi Y., Kimura K., Kinoshita M., Kamataki T. Homologous Unequal Cross-Over Within the Human CYP2A Gene Cluster as a Mechanism for the Deletion of Entire CYP2A6 Gene Associated with the Poor Metabolizer Phenotype. J. Biochem. 1999; 126: 402–407
   PubMed Web of Science ®Google Scholar
• Oscarson M., McLellan R.A., Gullstén H., Yue Q.-Y., Lang M.A., Bernal M.L., Sinues B., Hirvonen A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Characterization and PCR-Based Detection of a CYP2A6 Gene Deletion Found at a High Frequency in a Chinese Population. FEBS Lett. 1999; 448: 105–110
   PubMed Web of Science ®Google Scholar
• Rao Y., Hoffmann E., Zia M., Bodin L., Zeman M., Sellers E.M., Tyndale R.F. Duplications and Defects in the CYP2A6 Gene: Identification, Genotyping, and In Vivo Effects on Smoking. Mol. Pharmacol. 2000; 58: 747–755
   PubMed Web of Science ®Google Scholar
• Kitagawa K., Kunugita N., Kitagawa M., Kawamoto T. CYP2A6*6, a Novel Polymorphism in Cytochrome P450 2A6, Has a Single Amino Acid Substitution (R128Q) That Inactivates Enzymatic Activity. J. Biol. Chem. 2001; 276: 17830–17835
   PubMed Web of Science ®Google Scholar
• Ariyoshi N., Sawamura Y., Kamataki T. A Novel Single Nucleotide Polymorphism Altering Stability and Activity of CYP2A6. Biochem. Biophys. Res. Commun. 2001; 281: 810–814
   PubMed Web of Science ®Google Scholar
• Yoshida R., Nakajima M., Watanabe Y., Kwon J.T., Yokoi T. Genetic Polymorphisms in Human CYP2A6 Gene Causing Impaired Nicotine Metabolism. Br. J. Clin. Pharmacol., in press
   Google Scholar
• Xu C., Rao Y.S., Hoffmann E., Jones J., Sellers E.M., Tyndale R.F. An In Vivo Pilot Study Characterizing the New CYP2A6*7, *8, and *10 Alleles. Biochem. Biophys. Res. Commun. 2002; 290: 318–324
   PubMed Web of Science ®Google Scholar
• Daigo S., Takahashi Y., Fujieda M., Ariyoshi N., Yamazaki H., Koizumi W., Tanabe S., Saigenji K., Nagayama S., Ikeda K., Nishioka Y., Kamataki T. A Novel Mutant Allele of the CYP2A6 Gene (CYP2A6*11) Found in a Cancer Patient Who Showed Poor Metabolic Phenotype Towards Tegafur. Pharmacogenetics 2002; 12: 299–306
   PubMedGoogle Scholar
• Oscarson M., Gullstén H., Rautio A., Bernal M.L., Sinues B., Dahl M.-L., Stengård J.H., Pelkonen O., Raunio H., Ingelman-Sundberg M. Genotyping of Human Cytochrome P450 2A6 (CYP2A6), a Nicotine C-Oxidase. FEBS Lett. 1998; 438: 201–205
   PubMed Web of Science ®Google Scholar
• Bourian M., Gullstén H., Legrum W. Genetic Polymorphism of CYP2A6 in the German Population. Toxicology 2000; 144: 129–137
   PubMed Web of Science ®Google Scholar
• Chen G.-F., Tang Y.-M., Green B., Lin D.-X., Guengerich F.P., Daly A.K., Caporaso N.E., Kadlubar F.F. Low Frequency of CYP2A6 Gene Polymorphism as Revealed by a One-Step Polymerase Chain Reaction Method. Pharmacogenetics 1999; 9: 327–332
   PubMedGoogle Scholar
• Pelkonen O., Rautio A., Raunio H., Pasanen M. CYP2A6: A Human Coumarin 7-Hydroxylase. Toxicology 2000; 144: 139–147
   PubMed Web of Science ®Google Scholar
• Pitarque M., von Ritchter O., Oke B., Berkkan H., Oscarson M., Ingelman-Sundberg M. Identification of a Single Nucleotide Polymorphism in the TATA Box of the CYP2A6 Gene: Impairment of Its Promoter Activity. Biochem. Biophys. Res. Commun. 2001; 284: 455–460
   PubMed Web of Science ®Google Scholar
• Kitagawa K., Kunugita N., Katoh T., Yang M., Kawamoto T. The Significance of the Homozygous CYP2A6 Deletion on Nicotine Metabolism: A New Genotyping Method of CYP2A6 Using a Single PCR-RFLP. Biochem. Biophys. Res. Commun. 1999; 262: 146–151
   PubMed Web of Science ®Google Scholar
• Yang M., Kunugita N., Kitagawa K., Kang S.H., Coles B., Kadlubar F.F., Katoh T., Matsuno K., Kawamoto T. Individual Differences in Urinary Cotinine Levels in Japanese Smokers: Relation to Genetic Polymorphism of Drug-Metabolizing Enzymes. Cancer Epidemiol. Biomark. Prev. 2001; 10: 589–593
   PubMed Web of Science ®Google Scholar
• Benowitz N.L., Griffin C., Tyndale R. Deficient C-Oxidation of Nicotine Continued. Clin. Pharmacol. Ther. 2001; 70: 567
   PubMed Web of Science ®Google Scholar
• Benowitz N.L. Pharmacologic Aspects of Cigarette Smoking and Nicotine Addiction. N. Engl. J. Med. 1988; 319: 1318–1330
   PubMed Web of Science ®Google Scholar
• Pianezza M.L., Sellers E.M., Tyndale R.F. Nicotine Metabolism Defect Reduces Smoking. Nature 1998; 393: 750
   PubMed Web of Science ®Google Scholar
• Gu D.F., Hinks L.J., Morton N.E., Day I.N.M. The Use of Long PCR to Confirm Three Common Alleles at the CYP2A6 Locus and the Relationship Between Genotype and Smoking Habit. Ann. Hum. Genet. 2000; 64: 383–390
   PubMed Web of Science ®Google Scholar
• London S.J., Idle J.R., Daly A.K., Coetzee G.A. Genetic Variation of CYP2A6, Smoking, and Risk of Cancer. Lancet 1999; 353: 898–899
   PubMed Web of Science ®Google Scholar
• Sabol S.Z., Hamer D.H. An Improved Assay Shows No Association Between the CYP2A6 Gene and Cigarette Smoking Behavior. Behav. Genet. 1999; 4: 257–261
   Google Scholar
• Tiihonen J., Pesonen U., Kauhanen J., Koulu M., Hallikainen T., Leskinen L., Salonen J.T. CYP2A6 Genotype and Smoking. Mol. Psychiatry 2000; 5: 347–349
   PubMed Web of Science ®Google Scholar
• Loriot M.-A., Rebuissou S., Oscarson M., Cenée S., Miyamoto M., Ayiyoshi N., Kamataki T., Hémon D., Beaune P., Stücker I. Genetic Polymorphisms of Cytochrome P450 2A6 in a Case–Control Study on Lung Cancer in a French Population. Pharmacogenetics 2001; 11: 39–44
   PubMedGoogle Scholar
• Zhang X., Ameno K., Ameno S., Iwahashi K., Kinoshita H., Kubota T., Mostofa J., Ijiri I. Lack of Association Between Smoking and CYP2A6 Gene Polymorphisms in a Japanese Population. Jpn. J. Alcohol Drug Depend. 2001; 36: 486–490
   Google Scholar
• Schultz T.G., Ruhnau P., Hallier E. Lack of Correlation Between CYP2A6 Genotype and Smoking Habits. Adv. Exp. Med. Biol. 2001; 500: 213–215
   PubMed Web of Science ®Google Scholar
• McKinney E.F., Walton R.T., Yudkin P., Fuller A., Haldar N.A., Mant D., Murphy M., Welsh K.I., Marshall S.E. Association Between Polymorphisms in Dopamine Metabolic Enzymes and Tobacco Consumption in Smokers. Pharmacogenetics 2000; 10: 483–491
   PubMedGoogle Scholar
• Arinami T., Ishiguro H., Onaivi E.S. Polymorphisms in Genes Involved in Neurotransmission in Relation to Smoking. Eur. J. Pharmacol. 2000; 410: 216–226
   Google Scholar
• Yamazaki H., Inui Y., Yun C.-H., Guengerich F.P., Shimada T. Cytochrome P450 2E1 and 2A6 Enzymes as Major Catalysts for Metabolic Activation of N-Nitrosodialkylamines and Tobacco-Related Nitrosoamine in Human Liver Microsomes. Carcinogenesis 1992; 13: 1789–1794
   PubMed Web of Science ®Google Scholar
• Miyamoto M., Umetsu Y., Dosaka-Akita H., Sawamura Y., Yokota J., Kunitoh H., Nemoto N., Sato K., Ariyoshi N., Kamataki T. CYP2A6 Gene Deletion Reduces Susceptibility to Lung Cancer. Biochem. Biophys. Res. Commun. 1999; 261: 658–660
   PubMed Web of Science ®Google Scholar
• Gullstén, H.; Oscarson, M.; McLellan, R.A.; Ingelman-Sundberg, M.; Anttila, S.; Rautio, A.; Pelkonen, O.; Raunio, H.; Hirvonen, A. CYP2A6 Polymorphism and Lung Cancer Risk in the Finnish Population, Abstract of 13th International Symposium on Microsomes and Drug Oxidations, Italy, 2000; 112.
   Google Scholar
• Tan W., Chen G.-F., Xing D.-Y., Song C.-Y., Kadlubar F.F., Lin D.-X. Frequency of CYP2A6 Gene Deletion and Its Relation to Risk of Lung and Esophageal Cancer in the Chinese Population. Int. J. Cancer 2001; 95: 96–101
   PubMed Web of Science ®Google Scholar
• Gullstén H., Agundez J.A., Benitez J., Laara E., Ladero J.M., Diaz-Rubio M., Fernandez-Salguero P., Gonzalez F.J., Rautio A., Pelkonen O., Raunio H. CYP2A6 Gene Polymorphism and Risk of Liver Cancer and Cirrhosis. Pharmacogenetics 1997; 7: 247–250
   PubMedGoogle Scholar
• Kamataki T., Nunoya K.-I., Sakai Y., Kushida H., Fujita K.-I. Genetic Polymorphism of CYP2A6 in Relation to Cancer. Mutat. Res. 1999; 428: 125–130
   PubMed Web of Science ®Google Scholar
• Nunoya K., Yokoi T., Kimura K., Kodama T., Funayama M., Inoue K., Nagashima K., Funae Y., Shimada N., Green C., Kamataki T. (+)-Cis-3,5-dimethyl-2-(3-pyridyl9thiazolidin-4-one hydrochloride (SM-12502) as a Novel Substrate for Cytochrome P450 2A6 in Human Liver Microsomes. J. Pharmacol. Exp. Ther. 1996; 277: 768–774
   PubMed Web of Science ®Google Scholar
• Spracklin D.K., Kharasch E.D. Human Halothane Reduction In Vitro by Cytochrome P450 2A6 and 3A4: Identification of Low and High Km Isoforms. Drug Metab. Dispos. 1998; 26: 605–607
   PubMed Web of Science ®Google Scholar
• Kharasch E.D., Hankins D.C., Thummel K.E. Human Kidney Methoxyflurane and Sevoflurane Metabolism. Intrarenal Fluoride Production as a Possible Mechanism of Methoxyflurane Nephrotoxicity. Anesthesiology 1995; 82: 689–699
   PubMed Web of Science ®Google Scholar
• Torchin C.D., McNeilly P.J., Kapetanovic I.M., Strong J.M., Kupferberg H.J. Stereoselective Metabolism of a New Anticonvulsant Drug Candidate, Losigamone, by Human Liver Microsomes. Drug Metab. Dispos. 1996; 24: 1002–1008
   PubMed Web of Science ®Google Scholar
• Wirz B., Valles B., Parkinson A., Madan A., Probst A., Zimmerlin A., Gut J. CYP3A4 and CYP2A6 Are Involved in the Biotransformation of Letrozole. ISSX Proc. 1996; 10: 359
   Google Scholar
• Walter B.A., Hundal J.S. In Vitro Metabolism of Fadrozole (VGS 16949A) in Human Microsomes and Human Cell Lines Expressing a Single P450 Isozyme. ISSX Proc. 1994; 6: 187
   Google Scholar
• Sadeque A.J.M., Fisher M.B., Korzekwa K.R., Gonzalez F.J., Rettie A.E. Human CYP2C9 and CYP2A6 Mediate Formation of the Hepatotoxin 4-Ene-valproic Acid. J. Pharmacol. Exp. Ther. 1997; 283: 698–703
   PubMed Web of Science ®Google Scholar
• Madan A., Parkinson A., Faiman M.D. Identification of the Human and Rat P450 Enzymes Responsible for the Sulfoxidation of S-Methyl N,N-Diethylthiolcarbamate (DETC-ME). The Terminal Step in the Bioactivation of Disulfiram. Drug Metab. Dispos. 1995; 23: 1153–1162
   PubMed Web of Science ®Google Scholar
• Komatsu T., Yamazaki H., Shimada N., Nakajima M., Yokoi T. Roles of Cytochrome P450 1A2, 2A6, and 2C8 in 5-Fluorouracil Formation from Tegafur, an Anti-cancer Prodrug, in Human Liver Microsomes. Drug Metab. Dispos. 2000; 28: 1457–1463
   PubMed Web of Science ®Google Scholar
• Ikeda K., Yoshisue K., Matsushima E., Nagayama S., Kobayashi K., Tyson C.A., Chiba K., Kawaguchi Y. Bioactivation of Tegafur to 5-Fluorouracil Is Catalyzed by Cytochrome P-450 2A6 in Human Liver Microsomes In Vitro. Clin. Cancer Res. 2000; 6: 4409–4415
   PubMed Web of Science ®Google Scholar